Knight Therapeutics (TSE:GUD) Hits New 1-Year High – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD – Get Free Report) reached a new 52-week high on Monday . The stock traded as high as C$8.91 and last traded at C$8.88, with a volume of 33668 shares trading hands. The stock had previously closed at C$8.61.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group set a C$9.50 target price on Knight Therapeutics and gave the company a “buy” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of C$9.50.

Get Knight Therapeutics alerts:

Check Out Our Latest Stock Report on GUD

Knight Therapeutics Stock Up 0.7%

The company has a debt-to-equity ratio of 8.86, a current ratio of 2.32 and a quick ratio of 1.79. The firm has a market capitalization of C$903.25 million, a P/E ratio of 153.33, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.14. The business has a 50 day moving average price of C$7.96 and a 200 day moving average price of C$6.76.

Knight Therapeutics (TSE:GUD – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 earnings per share (EPS) for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%.The firm had revenue of C$147.59 million for the quarter. On average, analysts predict that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

Knight Therapeutics Company Profile

(Get Free Report)

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Further Reading

• Five stocks we like better than Knight Therapeutics
• Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand
• Optical Cable Corporation: Strong Earnings, But Hurdles Remain
• The Bank of Mom and Dad Is Booming—3 Stocks to Watch
• Corning Is Paving AI’s Future With Glass

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.